Clinical Read2026-06-12
Etentamig (ABBV-383) (BCMAxCD3 Bispecific)
AbbVieABBV
- Indication
- Relapsed Or Refractory Light Chain Amyloidosis
- Stage
- Phase 1/2
- Event
- Phase 1/2 Data readout
- Details
06/08/26:- M24-209 Ph1/2 etentamig amyloidosis data to be presented at EHA 2026 June 12.
- Source
- View catalyst source ↗
Financial Snapshot
Market Cap
$394.1B
Price
$225.42